|
?:authorAffiliation
|
-
[\'Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.\', \'IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, USA.\', \'Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, USA.\', \'Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.\', \'Division of Infectious Diseases, Department of Medicine, University of California, San Diego, La Jolla, CA, USA.\', \'Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA. burton@scripps.edu.\', \'IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, USA. burton@scripps.edu.\', \'Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, USA. burton@scripps.edu.\', \'Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, MA, USA. burton@scripps.edu.\', \'Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA. andrabi@scripps.edu.\', \'IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, USA. andrabi@scripps.edu.\', \'Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, USA. andrabi@scripps.edu.\']
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}